Alejandro Falcón

1.0k total citations
29 papers, 135 citations indexed

About

Alejandro Falcón is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alejandro Falcón has authored 29 papers receiving a total of 135 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Alejandro Falcón's work include Lung Cancer Research Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). Alejandro Falcón is often cited by papers focused on Lung Cancer Research Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). Alejandro Falcón collaborates with scholars based in Spain, United States and United Kingdom. Alejandro Falcón's co-authors include María Ángeles Castilla, Marta Benavent, Javier Salvador Bofill, Manuel Ruíz-Borrego, Sonia Molina‐Pinelo, Atanasio Pandiella, Carmen Kahatt, M.J. Flor, M.J. Escudero and Federico Rojo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Alejandro Falcón

25 papers receiving 134 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alejandro Falcón Spain	6	89	54	44	24	22	29	135
Mohammad Atiq United States	6	88 1.0×	54 1.0×	64 1.5×	26 1.1×	8 0.4×	21	155
Ray Manneh Kopp Spain	9	69 0.8×	38 0.7×	83 1.9×	44 1.8×	18 0.8×	35	172
Cody Weimholt United States	7	63 0.7×	91 1.7×	67 1.5×	33 1.4×	10 0.5×	15	168
Georgia Makrypidi‐Fraune Germany	6	52 0.6×	50 0.9×	33 0.8×	18 0.8×	21 1.0×	7	125
Ilona Pylvaenaeinen Switzerland	7	101 1.1×	66 1.2×	42 1.0×	24 1.0×	8 0.4×	8	164
David König Switzerland	7	145 1.6×	83 1.5×	95 2.2×	34 1.4×	24 1.1×	26	247
Gert Van den Eyden Belgium	4	133 1.5×	31 0.6×	27 0.6×	28 1.2×	7 0.3×	4	193
Mariko Tabata Japan	5	47 0.5×	77 1.4×	44 1.0×	49 2.0×	9 0.4×	12	148
Michel Velez United States	6	54 0.6×	71 1.3×	50 1.1×	24 1.0×	9 0.4×	16	110
Kylie Prutisto-Chang United States	2	85 1.0×	62 1.1×	119 2.7×	47 2.0×	16 0.7×	3	162

Countries citing papers authored by Alejandro Falcón

Since Specialization

Citations

This map shows the geographic impact of Alejandro Falcón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Falcón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Falcón more than expected).

Fields of papers citing papers by Alejandro Falcón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Falcón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Falcón. The network helps show where Alejandro Falcón may publish in the future.

Co-authorship network of co-authors of Alejandro Falcón

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Falcón. A scholar is included among the top collaborators of Alejandro Falcón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Falcón. Alejandro Falcón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doger, Bernard, Jeffrey Yachnin, Irene Moreno, et al.. (2025). 581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients. Regular and Young Investigator Award Abstracts. A660–A661.

Falcón, Alejandro, Santiago Ponce, Gregory M. Coté, et al.. (2025). Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors. Investigational New Drugs. 43(4). 955–967.

Falcón, Alejandro, Josefina Cruz Jurado, Pedro Sánchez‐Rovira, et al.. (2024). Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. Clinical & Translational Oncology. 26(9). 2217–2226. 2 indexed citations

Falcón, Alejandro, et al.. (2024). Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients. Clinical & Translational Oncology. 27(3). 909–934.

Benavent, Marta, María Ángeles Castilla, Begoña Vieites, et al.. (2024). Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression. Therapeutic Advances in Medical Oncology. 16. 12753905–12753905. 1 indexed citations

Paz‐Ares, Luis, Alejandro Falcón, Alejandro Navarro, et al.. (2024). Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.. Journal of Clinical Oncology. 42(16_suppl). 8094–8094. 1 indexed citations

Falcón, Alejandro, et al.. (2023). Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 41(16_suppl). e12608–e12608.

Llombart‐Cussac, Antonio, Beatriz Rojas, Raquel Andrés, et al.. (2023). Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers. 15(5). 1529–1529. 2 indexed citations

Mar, Nataliya, Yousef Zakharia, Alejandro Falcón, et al.. (2023). Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers. 15(11). 2978–2978. 1 indexed citations

10.

Castilla, María Ángeles, Alejandro Falcón, Marta Benavent, et al.. (2023). Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences. 24(10). 8488–8488. 31 indexed citations

11.

Patel, Manish R., JS Lee, Maria J. de Miguel, et al.. (2022). 459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation. Annals of Oncology. 33. S749–S749. 6 indexed citations

12.

Falcón, Alejandro, et al.. (2021). Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure. Cancer Treatment and Research Communications. 27. 100314–100314. 1 indexed citations

13.

Ponce-Aix, Santiago, Gregory M. Coté, Alejandro Falcón, et al.. (2021). OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial. Journal of Thoracic Oncology. 16(3). S127–S127. 11 indexed citations

14.

Herrero, Daniel, et al.. (2020). Assessment of Prognostic and Therapeutic Factors in Male Breast Cancer: An Observational Study of a Southwest Spanish Single Center. SHILAP Revista de lepidopterología. 155–163. 1 indexed citations

15.

Ocaña, Alberto, Marta Gil-Martín, Silvia Antolín, et al.. (2019). Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment. 174(3). 693–701. 36 indexed citations

16.

Ponce, Santiago, Emiliano Calvo, Maria J. de Miguel, et al.. (2019). P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials. Journal of Thoracic Oncology. 14(10). S817–S817. 3 indexed citations

17.

Gullo, Giuseppe, Séamus O’Reilly, Manuel Ruíz‐Borrego, et al.. (2019). Abstract OT3-06-01: Phase Ib clinical trial of coPANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive breAst cancer (BC) “PANTHERA”-CTRIAL-IE 17-13. Cancer Research. 79(4_Supplement). OT3–6. 1 indexed citations

18.

Borrego, Manuel Ruíz, Marta Gil-Martín, Silvia Antolín, et al.. (2017). A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Annals of Oncology. 28. v75–v75. 1 indexed citations

19.

Falcón, Alejandro, et al.. (2017). P3.02c-034 A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1293–S1294. 1 indexed citations

20.

Munhoz, Rodrigo Ramella, et al.. (2015). Targeting Immune Checkpoints in Melanoma: An Update. PubMed. 2(4). 339–352. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact